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A multidisciplinary group of experts gathered in Parma Italy for a workshop hosted by the University of Parma, May
16–18, 2014 to address concerns about the potential relationship between environmental metabolic disrupting
chemicals, obesity and related metabolic disorders. The objectives of the workshop were to: 1. Review findings
related to the role of environmental chemicals, referred to as “metabolic disruptors”, in obesity and metabolic
syndrome with special attention to recent discoveries from animal model and epidemiology studies; 2. Identify
conclusions that could be drawn with confidence from existing animal and human data; 3. Develop predictions
based on current data; and 4. Identify critical knowledge gaps and areas of uncertainty. The consensus statements
are intended to aid in expanding understanding of the role of metabolic disruptors in the obesity and metabolic
disease epidemics, to move the field forward by assessing the current state of the science and to identify research
needs on the role of environmental chemical exposures in these diseases. We propose broadening the definition of
obesogens to that of metabolic disruptors, to encompass chemicals that play a role in altered susceptibility to
obesity, diabetes and related metabolic disorders including metabolic syndrome.
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Obesity and related metabolic diseases
There is now convincing evidence that shows a dramatic
increase in the incidence of a set of related clinical phe-
notypes and diseases linked to the metabolic syndrome
over the last 4 decades. Metabolic syndrome is charac-
terized by a cluster of symptoms including insulin resist-
ance, hyperglycemia, abdominal obesity, dyslipidemia, and
hypertension [1] that occur together, increasing risk for
type 2 diabetes, cardiovascular disease (angina, hyperten-
sion, stroke, heart attack), liver diseases (steatosis), inflam-
matory and immune disorders [1, 2]. Obesity is defined as
having a body mass index (BMI) > 30 kg/square meter and* Correspondence: heindelj@niehs.nih.gov
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decades in the United States [3]. Type 2 diabetes increased
by 30.5 % in children and adolescents in the USA between
2001–2009 [4]. Type 2 was once referred to as “adult on-
set diabetes”, but it is now rapidly increasing in incidence
in children and adolescents concurrently with the increase
in childhood obesity [5]. Visceral (intra-abdominal) fat ac-
cumulation appears to be a major risk factor for the other
components of metabolic syndrome [6]. Finally, the in-
creasing incidence of metabolic syndrome is recognized as
a global health problem, not just a problem of developed
countries [7].
The current focus on the etiology of increased obesity
remains on imbalance between food intake and energy ex-
penditure. Although clinicians continue to recommend re-
ducing calorie intake and increasing exercise [6], data
show that once a person is overweight or obese, effectiverticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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who achieve significant weight loss do not maintain it.
Obesity is a complex endocrine disease caused by disrup-
tion of many hormonal control systems that link the
gastro-intestinal tract, pancreas, muscle, adipose tissue,
liver and brain, and involves an interaction between gen-
etic and environmental factors. Furthermore the hypothal-
amic pituitary axis and or and/or hypothalamic gonadal
axis function affects in turn energy balance and metabolic
function.
Given the limited success reversing the obesity epi-
demic and related morbidities by focusing solely on nu-
trition, exercise or drug therapies, there is a compelling
need to consider other potential environmental factors
that could be major contributors to visceral adiposity
and other aspects of metabolic syndrome that are in-
creasing at a dramatic rate worldwide. For example, a re-
cent study showed that animals (feral animals in cities,
pets, laboratory animals) living in proximity to humans
are becoming obese in parallel with humans over the
past few decades [8]. This observation strongly supports
the existence of additional factors beyond energy balance
in the obesity epidemic.
Endocrine disruption and the Developmental Origins of
Health and Disease (DOHaD)
Extensive evidence from human and animal research
shows that disruption of metabolic systems during “crit-
ical windows” in development can lead to permanent
changes that impact the likelihood of developing a var-
iety of non-communicable diseases. These include obes-
ity and components of metabolic syndrome, with the
specific systems affected determined by the type and
timing of developmental exposure. This Developmental
Origins of Health and Disease (DOHaD) hypothesis [2,
9] holds that early life (e.g., in utero development, the
neonatal period and childhood, when tissues and body
systems are developing and malleable) is a extraordinar-
ily sensitive time during which stressors (e.g., diet or
EDCs) can alter gene expression, protein levels, cell
numbers, fate or locations to cause changes in tissue
and organ function. These changes persist after the
stressor is gone and lead to increased susceptibility to
disease and dysfunctions later in life. There are no
known classical genetic mechanisms that could explain
the remarkable changes in body composition that have
occurred over recent decades. Therefore, there has been
a significant focus on identifying changes in gene expres-
sion and epigenetic marks caused by environmental fac-
tors, such as stress [10], drugs (for example nicotine)
and a number of endocrine disrupting chemicals during
development (in utero and early childhood) in relation
to the risk of metabolic diseases later in life [11–14].The obesogen hypothesis
Endocrine disrupting chemicals (EDCs) are a subclass of
toxic chemicals that act by altering some aspect of hor-
mone action (reviewed in [15]). Animal and human ex-
posure data show that a variety of EDCs can act as
“obesogens”, during development with exposures during
critical periods in organogenesis, around puberty and in
adulthood being related to an increase in central fat de-
position and function [16–19]. Obesogens can act to
promote obesity by increasing the number and size of
fat cells, by shifting energy balance to favor calorie stor-
age, by altering basal metabolic rate, by altering gut
microbiota to promote food storage [20] by altering hor-
monal control of appetite and satiety [17, 18, 21, 22] and
by altering brain circuitries controlling food intake and
energy expenditure [23]. Some EDCs have been found to
impact insulin levels together with vascular, immune,
liver and cardiovascular function.
New obesogenic chemicals are being identified at an
increasing rate. These include estrogenic EDCs such as
diethylstilbestrol (DES) [24], bisphenol A (BPA) [25, 26],
DDT [27, 28], organotins such as tributyltin (TBT) [29,
30], perfluorooctanoates [31] and phthalates [32–34]. All
of these chemicals show obesogenic properties in labora-
tory animals. In humans urinary phthalate levels have
been correlated with increased waist diameter [35, 36]
and urinary BPA has been correlated with obesity in
children and adolescents [37, 38] and adults [39]. Several
persistent organic pollutants (e.g., DDE, HCB, polybro-
minated diphenyl ethers) have been linked with obesity
in humans [40, 41].
The effects of prenatal exposure to some obesogens
persist until at least the F3 generation. This is significant
because in multigeneration studies, F0 and F1 animals
are directly exposed to the test chemical; F2 are exposed
as germ cells within F1 animals. The F3 is the first gen-
eration that has not received any direct chemical expos-
ure; therefore, effects observed in F3 and beyond are
considered to be transgenerational and permanent.
Transgenerational effects are distinct from the multigener-
ational effects in F1 and F2 animals [14, 42] ( see reference
41 for figure depicting transgenerational effects). Exposure
of pregnant F0 animals to low, environmentally-relevant
levels of TBT in their drinking water led to increased
fat depot size, reprogramming of multipotent mesen-
chymal stem cells toward the adipogenic lineage and
hepatic steatosis through the F3 generation [29]. Pre-
natal TBT exposure is thus a maternal programming
event that permanently altered stem cell fate leading to
a reproducible adult phenotype. Skinner and colleagues
have shown that plastic components such as BPA,
diethylhexyl phthalate and dibutyl phthalate [34], a
mixed hydrocarbon mixture (jet fuel JP-8) [43], and the
once widely used environmentally persistent pesticide,
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to obesity in the F3 generation (among other adverse
outcomes). Taken together, these observations support
the relevance of the obesogen hypothesis. Nonetheless the
obesogen hypothesis has been largely overlooked by the
medical community as a contributing factor to obesity.
Parma meeting
A multidisciplinary group of experts (epidemiologists,
biologists, toxicologists, endocrinologists, neurobiolo-
gists, risk assessors, molecular biologists, and clinicians
with an interest in the role of environmental chemicals
in obesity, diabetes and metabolic syndrome) gathered in
Parma Italy for a workshop/brainstorming session hosted
by the University of Parma, May 16–18, 2014. This was
the first international working group to focus on the role
of environmental chemicals exposures in obesity and
metabolic syndrome. The objective of the conference was
to bring together scientists from a variety of disciplines to
examine the relationship between EDC exposure and the
increased incidence of metabolic disorders in many popu-
lations, including obesity, diabetes, cardiovascular disease,
hypertension and kidney disease (Table 1).
The workshop opened with a general discussion of the
state of the science linking endocrine disruptors with
obesity/diabetes/metabolic syndrome. The following day
there were sessions discussing evidence from animal
models, human epidemiology studies, integrating human
and animal data, expanding endpoints in animal and hu-
man studies, improving study designs, windows of suscep-
tibility and developmental programming and epigenetics.
The final session focused on defining a path forward, in-
cluding integration of the obesogen/metabolic disruptor
hypothesis into mainstream science. The results of this
workshop are presented here as a series of consensus
statements indicating what is known, where there are data
gaps, and what is needed to move this field forward toTable 1 The objectives of the Parma workshop were to
• Review findings related to the role of environmental chemicals in
obesity and metabolic syndrome with special attention to recent
discoveries from animal model and epidemiology studies.
• Discuss refocusing the science from obesogens (obesity focus) to a
more general focus on metabolic disruptors (metabolic syndrome).
• Identify conclusions that could be drawn with confidence from existing
animal and human data.
• Develop predictions based on current data.
• Identify critical knowledge gaps and areas of uncertainty.
• Develop ideas and plans for future research that would help fill data
gaps and resolve uncertainties that would lead to greater understanding
of the obesogen/metabolic disruptor paradigm by the wider scientific and
general communities.
• Develop plans to stimulate outreach to a wider scientific community
via symposia, review articles, teleconferences.prevent obesity, diabetes and other co-morbidities related
to metabolic disruption.
A major conclusion from the workshop was that the
word, obesogen, while it served an important purpose to
focus interest on EDCs and obesity, had become too re-
strictive. While there may be chemicals that only in-
crease susceptibility to obesity (and are appropriately
called obesogens), there are environmental chemicals
that can cause other aspects of metabolic syndrome as
well as diabetes. For example, humans are exposed to
bisphenol A via polycarbonate plastics, many can linings
and some cash register receipts; bisphenol A exposure in
rodent models results in increased weight, altered glu-
cose homeostasis, altered beta cell function, altered liver
lipids and cardiovascular dysfunction [26, 44–46]. How
many other chemicals would have multiple effects on me-
tabolism remains an open question. Thus, it was decided
that the field should change from using the specific word
obesogen when referring to diseases other than obesity to
the more general term, “metabolic disruptor” as originally
proposed by Casas-Casas and Desvergne [47].
“Metabolic disruptor” hypothesis
We hypothesize that environmental chemicals can act
during development and/or other sensitive time periods
across the lifespan to control adipose tissue development
by increasing the number and/or size of fat cells and/or
by altering food intake and metabolism via specific ef-
fects on the brain, pancreas, adipose tissue, liver, GI tract
and muscle individually or in combination. These meta-
bolic disruptors thereby alter programming or sensitivity
for developing obesity/diabetes or aspects of metabolic
syndrome later in life.
Increased susceptibility to obesity/diabetes/metabolic
syndrome may result directly from exposure to the meta-
bolic disruptor or in other cases may require a second
“hit”, for example, increased fat or sugar in the diet and/or
stress for the functional change to be expressed as a
phenotype. The effects may be sexually dimorphic and the
dose responses may be non-monotonic in nature as is
often the case for EDCs [48, 49].
Consensus statement
We are confident of the following:
 There is a global increase in incidence of obesity,
diabetes and metabolic diseases.
 There is a global increase in childhood obesity and
type 2 diabetes.
 While there are genes that play important roles in
these diseases, like all complex diseases there must
be both genetic and environmental components.
 The increase in obesity and metabolic diseases over
the last 4 decades cannot be accounted for by
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some aspect of the environment.
 There is more to the environmental component of
obesity, diabetes and metabolic syndrome than
overeating and poor nutrition, lack of exercise and
changes in lifestyle. The environmental component
is multifactorial and includes prescription drugs,
stress, nutrition, microbiome, infections, sleep
patterns, nocturnal illumination and environmental
chemicals.
 Obesity and metabolic syndrome are endocrine
diseases/dysfunctions and thus sensitive to
disruption by environmental agents that can
interfere with hormone and neuroendocrine action
(e.g. EDCs).
 There are pharmaceutical obesogens - prescription
drugs with the known side effect of causing weight
gain.
 Susceptibility to metabolic disorders is, at least in
part, ‘programmed’ in utero and early postnatal life by
exposure to environmental factors including stress,
drugs, nutrition and environmental chemicals.
 Programming may alter brain appetite and/or satiety
centers as well as fat cell numbers and other aspects
of metabolism, including effects on control of the GI
tract, muscle, pancreas, liver functions, etc. (e.g.
altering the sensitivity for gaining weight).
We estimate with confidence that:
 Effects will be due to “multiple hits” of environmental
exposures and may occur only after a latent period of
months to decades, requiring a lifespan research
approach, including prospective human studies.
 There are multiple specific windows of enhanced
susceptibility to metabolic disruptors across the
lifespan, including paternal, in utero, early childhood,
pre-puberty, pregnancy (for the mother) menopause
and aging.
 Development, in utero and during the first few years
of life, is the most sensitive window of susceptibility
for metabolic disruption.
 The two sexes show differential susceptibility to
metabolic disruption as well as different critical
windows for, and different effects of, exposure.
 Understanding environmental effects on these
diseases requires sensitive measures of personal
exposures and sensitive endpoints to identify
phenotypes.
 Effects of EDC exposure will vary depending on
co-occurrence of other environmental stressors such
as prescription drugs, sleep, hypercaloric diet,
activity, stress, socioeconomic status, infections,
microbiome, anxiety-depression etc., requiring adetailed analysis of potential interacting and
confounding factors.
Existing data lead us to predict that:
 The effects of metabolic disruptors may be difficult
to detect at the individual level due to human genomic
variability creating a heterogeneous population
requiring a genomic and statistical approach.
 Some effects of metabolic disruptors may be
transgenerational, requiring a multigenerational
approach: a minimum of two generations for
paternal line effects and three generations for
maternal line effects.
 Effects of metabolic disruptors will likely be
dependent on the dose and route of exposure and
may exhibit non-monotonic dose responses; this will
require dose response studies and a pharmacokinetic
approach.
 We should expect effects to be due to multiple
chemicals with varying half-lives, metabolism,
persistence, tissue accumulation and target sensitivities;
complete analysis will require a mixtures approach.
 Certain metabolic disruptors will have specific
actions, causing only obesity, diabetes or altered liver
function whereas others will affect many aspects of
metabolism leading to metabolic syndrome.
 We are underestimating the importance of
metabolic disruptors in obesity, diabetes, and
metabolic syndrome because current research
designs focus on studying one or a small subset of
chemicals at a time, during limited windows of
sensitivity, in single tissues (including only one
adipose tissue) and often only endpoints related to a
single disease outcome per study.
 Reducing exposures to environmental chemicals and
improving nutrition during development offers the
possibility of preventing obesity and metabolic diseases.
 The totality of environmental effects on obesity
(drugs, chemicals, stress and nutrition) will likely be
greater than the effects of genetic predisposition.
Focus of future research
We believe a multidisciplinary and integrated research
strategy is needed to further test the hypothesis that meta-
bolic disruptors alter the sensitivity to develop obesity, dia-
betes and metabolic syndrome. To obtain meaningful
results in a reasonable time and improve health and well-
being of future generations, we believe that future research
should focus on:
 Characterizing adverse outcome pathways through
which metabolic disruptors lead to different
manifestations of metabolic syndrome.
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there, what the mechanisms are underlying a
window of sensitivity and how exposures to
metabolic disruptors in multiple windows (e.g.
developmental and later life exposures) interact
across the lifespan and generations.
 Defining the role of metabolic disruptors in type 1
and 2 diabetes.
 Examining multiple endpoints to determine
whether a chemical leads to multiple metabolic
disorders or only one or a subset of metabolic
diseases. Appropriate endpoints include adipose
tissue depots (including brown adipose tissue),
insulin and glucose metabolism, liver function
focusing on lipid metabolism, muscle metabolism,
inflammation, feeding behavior and neural
networks controlling food intake, food preference
and satiety patterns, GI effects and measures of
hypertension and cardiovascular disease, and the
interaction between the gut microbiome and EDC
exposure.
 Assessing epigenomic and other markers underlying
altered developmental programming of metabolic
functions and endpoints in human studies and in
animal models.
 Addressing susceptible exposure windows and
multiple outcome windows over the life course that
use mother-child cohorts and bio-banks.
 Developing studies to determine whether metabolic
disruptors alter the “set-point” or sensitivity for
gaining weight and the ability to lose weight and the
mechanism(s) for these effects.
 Examining sex differences and differences in adipose
depots in responses.
 Developing early biomarkers from developmental
exposure to environmental agents that are associated
with underlying causal mechanisms that can predict
disease outcomes later in life.
 Developing and validating in vivo and in vitro
screens to detect and prioritize metabolic disruptors.
 Adding robust and relevant endpoints to guideline
studies (used by regulatory agencies) to detect
various aspects of metabolic disruption other than
just body weight.
 Adding endpoints related to metabolism and
metabolic rate to assess energy efficiency.
 Improving exposure assessments in human studies:
integrate genetics, genomics, proteomics and
metabolomics with environmental exposures to
better understand the role of metabolic disruptors in
disease onset and severity.
 Assessing multiple chemicals, mixture studies, and
integration with other stressors including stress,
drugs, nutrition and infections. Developing an integrated conceptual approach
linking animal studies and endpoints with longitudinal
human cohort studies; improved collaborations
among epidemiologists, clinicians and animal
researchers through integrated research projects,
comparable markers of exposure assessment and
effects. Integrated scientific meetings will greatly aid
in the integration of these scientific fields with that of
metabolic disruptor research.
Summary and conclusions
The Parma workshop helped to focus this emerging field
by developing an overarching hypothesis for the role of
environmental chemicals in the current worldwide epi-
demics of obesity, diabetes and related metabolic dis-
eases. We hope that the consensus statements will aid in
expanding understanding of the possible role of meta-
bolic disruptors in these epidemics and have identified
research needs in order to provide more relevant data
on the role of environmental chemicals in these diseases.
The objective is both to indicate the strength of the
current data and to provide a roadmap for further studies.
A coherent, enhanced research agenda will help identify
strategies to prevent metabolic diseases through actions
that can be taken by individuals as well as public health
agencies. History shows that prevention is always the best
strategy. Increased understanding of the importance of the
metabolic disruptor hypothesis to the epidemics of obesity
and metabolic syndrome offers the potential for these
diseases to be mitigated by modifying exposures,
thereby creating a healthier environment for future
generations.
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